Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $391.8 million.

  • Keros Therapeutics' Cash from Financing Activities fell 99.91% to $140,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year decrease of 80.36%. This contributed to the annual value of $391.8 million for FY2024, which is 118.95% up from last year.
  • As of FY2024, Keros Therapeutics' Cash from Financing Activities stood at $391.8 million, which was up 118.95% from $179.0 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Cash from Financing Activities registered a high of $391.8 million during FY2024, and its lowest value of $28.6 million during FY2021.
  • Its 3-year average for Cash from Financing Activities is $230.4 million, with a median of $179.0 million in 2023.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first surged by 2,114,500.00% in 2020, then plummeted by 90.36% in 2021.
  • Keros Therapeutics' Cash from Financing Activities (Yearly) stood at $296.0 million in 2020, then plummeted by 90.36% to $28.6 million in 2021, then spiked by 321.40% to $120.3 million in 2022, then surged by 48.75% to $179.0 million in 2023, then skyrocketed by 118.95% to $391.8 million in 2024.